The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: Evaluation of the evidence

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 884-901

  Banister, Samuel D ^a,b   Kassiou, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Addiction; Alzheimer's disease; Anxiety; Central nervous system; Depression; Pain; Schizophrenia; Sigma receptor

Indexed keywords

4 (4 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 [4 (1,2,4 TRIAZOL 1 YL)BUTYL]PYRIDINE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; AMANTADINE; CHLORPROMAZINE; CITALOPRAM; CLORGYLINE; CUTAMESINE; DEXETIMIDE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; HYPERICIN; IMIPRAMINE; KF 10047; MS 377; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N ALLYLNORMETAZOCINE; NEUROLEPTIC AGENT; OPIPRAMOL; PANAMESINE; PENTAZOCINE; PERPHENAZINE; PIMOZIDE; PRASTERONE SULFATE; RIMCAZOLE; SELEGILINE; SERTRALINE; SIGMA RECEPTOR LIGAND; SIRAMESINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; AUTORADIOGRAPHY; BINDING AFFINITY; BRIEF PSYCHIATRIC RATING SCALE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM; FORCED SWIMMING TEST; HUMAN; IC 50; LOADING DRUG DOSE; LOCOMOTION; MOOD DISORDER; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PLACE PREFERENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE; SUBSTANTIA NIGRA; TAIL FLICK TEST; TREATMENT RESPONSE;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MENTAL DISORDERS; RECEPTORS, SIGMA;

EID: 84857130955     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436539     Document Type: Review

References (270)

1. Maurice T, Su T-P. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009; 124: 195-206.
2. Kulkarni SK, Dhir A. σ-1 receptors in major depression and anxiety. Expert Rev Neurother 2009; 9: 1021-34.
3. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005; 97: 317-36.
4. Hayashi T, Stahl SM. The sigma-1 (σ) receptor and its role in the treatment of mood disorders. Drugs Fut 2009; 34: 137-46.
5. Snyder SH, Largent BL. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry Clin Neurosci 1989; 1: 7-15.
6. Moller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59-65.
7. Heading C. Siramesine. Curr Opin Investig Drugs 2001; 2: 266-70.
8. Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004; 37 (Suppl 3): S214-20.
9. Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85-6.
10. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 1996; 229: 553-8.
11. Hayashi T, Su T-P. Sigma-1 receptor chaperones at the ERmitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007; 131: 596-610.
12. Tsai S-Y, Hayashi T, Mori T, Su T-P. Sigma-1 receptor chaperones and diseases. Cent Nerv Syst Agents Med Chem 2009; 9: 184-9.
13. Hayashi T, Su TP. Intracellular dynamics of σ-1 receptors (σ binding sites) in NG108-15 cells. J Pharmacol Exp Ther 2003; 306: 726-33.
14. Morin-Surun MP, Collin T, Denavit-Saubie M, Baulieu EE, Monnet FP. Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci USA 1999; 96: 8196-9.
15. Wilke RA, Lupardus PJ, Grandy DK, Rubinstein M, Low MJ, Jackson MB. K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J Physiol 1999; 517: 391-406.
16. 2+ concentration. J Pharmacol Exp Ther 2000; 293: 788-98.
17. Lupardus PJ, Wilke RA, Aydar E, et al. Membrane-delimited coupling between sigma receptors and K+ channels in rat neurohypophysial terminals requires neither G-protein nor ATP. J Physiol 2000; 526: 527-39.
18. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002; 34: 399-410.
19. Mavlyutov TA, Ruoho AE. Ligand-dependent localization and intracellular stability of sigma-1 receptors in CHO-K1 cells. J Mol Signal 2007; 2: 8.
20. Renaudo A, L'Hoste S, Guizouarn H, Borgese F, Soriani O. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl-channels. J Biol Chem 2007; 282: 2259-67.
21. Junien JL, Roman FJ, Brunelle G, Pascaud X. JO1784, a novel sigma ligand, potentiates [3H]acetylcholine release from rat hippocampal slices. Eur J Pharmacol 1991; 200: 343-5.
22. Kobayashi T, Matsuno K, Nakata K, Mita S. Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. J Pharmacol Exp Ther 1996; 279: 106-13.
23. Kobayashi T, Matsuno K, Mita S. Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain. J Neural Transm 1996; 103: 661-9.
24. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 1996; 306: 271-9.
25. Gonzalez GM, Werling LL. Release of [3H]dopamine from guinea pig striatal slices is modulated by sigma1 receptor agonists. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 356: 455-61.
26. Monnet FP, Debonnel G, Junien JL, De Montigny C. N-methyl-Daspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur J Pharmacol 1990; 179: 441-5.
27. Monnet FP, Debonnel G, de Montigny C. In vivo electrophysiological evidence for a selective modulation of Nmethyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 1992; 261: 123-30.
28. Gonzalez-Alvear GM, Werling LL. Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 1994; 271: 212-9.
29. Gonzalez-Alvear GM, Werling LL. sigma1 Receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 1995; 294: 713-9.
30. Gonzalez-Alvear GM, Werling LL. Sigma receptor regulation of norepinephrine release from rat hippocampal slices. Brain Res 1995; 673: 61-9.
31. Hayashi T, Kagaya A, Takebayashi M, et al. Modulation by [1] ligands of intracellular free Ca++ mobilization by N-methyl-Daspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 1995; 275: 207-14.
32. Monnet FP, Mahe V, Robel P, Baulieu EE. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 1995; 92: 3774-8.
33. Monnet FP, de Costa BR, Bowen WD. Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked[3H]-noradrenaline release in rat hippocampal slices. Br J Pharmacol 1996; 119: 65-72.
34. Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-Daspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J Endocrinol 1996; 150 (Suppl): S33-42.
35. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996; 58: 721-34.
36. Hayashi T, Su TP, Kagaya A, Nishida A, Shimizu M, Yamawaki S. Neuroleptics with differential affinities at dopamine D2 receptors and sigma receptors affect differently the N-methyl-D-aspartateinduced increase in intracellular calcium concentration: involvement of protein kinase. Synapse 1999; 31: 20-8.
37. Bermack JE, Debonnel G. Modulation of serotonergic neurotransmission by short-and long-term treatments with sigma ligands. Br J Pharmacol 2001; 134: 691-9.
38. Lucas G, Rymar VV, Sadikot AF, Debonnel G. Further evidence for an antidepressant potential of the selective σ1 agonist SA 4503: electrophysiological, morphological and behavioural studies. Int J Neuropsychopharmacol 2008; 11: 485-95.
39. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990; 527: 244-53.
40. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994; 268: 9-18.
41. Zeng C, Vangveravong S, Xu J, et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 2007; 67: 6708-16.
42. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997; 57: 156-61.
43. Wheeler KT, Wang LM, Wallen CA, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000; 82: 1223-32.
44. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995; 55: 408-13.
45. John CS, Bowen WD, Varma VM, McAfee JG, Moody TW. Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci 1995; 56: 2385-92.
46. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62: 313-22.
47. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005; 65: 8975-83.
48. Xu J, Zeng C, Chu Wx, et-al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011; 2: in press.
49. Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci 1986; 6: 1757-70.
50. Mash DC, Zabetian CP. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 1992; 12: 195-205.
51. McLean S, Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 1988; 25: 259-69.
52. Jansen KL, Dragunow M, Faull RL. Sigma receptors are highly concentrated in the rat pineal gland. Brain Res 1990; 507: 158-160.
53. Walker JM, Bowen WD, Goldstein SR, et al. Autoradiographic distribution of [3H](+)-pentazocine and [3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study. Brain Res 1992; 581: 33-8.
54. Leitner ML, Hohmann AG, Patrick SL, Walker JM. Regional variation in the ratio of [1][1] to [1]2 binding in rat brain. Eur J Pharmacol 1994; 259: 65-9.
55. McCann DJ, Weissman AD, Su TP. Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns. Synapse 1994; 17: 182-9.
56. Bouchard P, Quirion R. [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative σ1 and σ2 receptor subtypes. Neuroscience 1997; 76: 467-77.
57. Weissman AD, Su TP, Hedreen JC, London ED. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 1988; 247: 29-33.
58. Jansen KL, Faull RL, Dragunow M, Leslie RA. Autoradiographic distribution of sigma receptors in human neocortex, hippocampus, basal ganglia, cerebellum, pineal and pituitary glands. Brain Res 1991; 559: 172-7.
59. Dumont M, Lemaire S. Interaction of 1,3-di(2-[5-3H]tolyl) guanidine with sigma 2 binding sites in rat heart membrane preparations. Eur J Pharmacol 1991; 209: 245-8.
60. ++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 1994; 269: 1300-9.
61. Wolfe SA, Jr., Culp SG, De Souza EB. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989; 124: 1160-72.
62. Jansen KL, Elliot M, Leslie RA. sigma receptors in rat brain and testes show similar reductions in response to chronic haloperidol. Eur J Pharmacol 1992; 214: 281-3.
63. Roman F, Pascaud X, Chomette G, Bueno L, Junien JL. Autoradiographic localization of sigma opioid receptors in the gastrointestinal tract of the guinea pig. Gastroenterology 1989; 97: 76-82.
64. Craviso GL, Musacchio JM. High-affinity dextromethorphan binding sites in guinea pig brain. II. Competition experiments. Mol Pharmacol 1983; 23: 629-40.
65. Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF. 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigmatype receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 1986; 83: 8784-8.
66. Samovilova NN, Nagornaya LV, Vinogradov VA. (+)-[3H]SK&F 10,047 binding sites in rat liver. Eur J Pharmacol 1988; 147: 259-64.
67. Klein M, Musacchio JM. High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents. J Pharmacol Exp Ther 1989; 251: 207-15.
68. DeHaven-Hudkins DL, Fleissner LC. Competitive interactions at [3H]1,3-di(2-tolyl)guanidine (DTG)-defined sigma recognition sites in guinea pig brain. Life Sci 1992; 50: PL 65-70.
69. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988; 240: 219-21.
70. Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 1999; 81: 125-55.
71. Gibbs TT, Farb DH. Dueling enigmas: neurosteroids and sigma receptors in the limelight. Sci. STKE 2000; 2000: PE1.
72. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Rev 2001; 37: 116-32.
73. Monnet FP, Maurice T. The sigma1 protein as a target for the nongenomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci, 2006; 100: 93-118.
74. McCann DJ, Su TP. Solubilization and characterization of haloperidol-sensitive (+)-[3H]SKF-10,047 binding sites (sigma sites) from rat liver membranes. J Pharmacol Exp Ther 1991; 257: 547-54.
75. Maurice T, Roman FJ, Privat A. Modulation by neurosteroids of the in vivo (+)-[3H]SKF-10,047 binding to sigma 1 receptors in the mouse forebrain. J Neurosci Res 1996; 46: 734-43.
76. Phan VL, Su TP, Privat A, Maurice T. Modulation of steroidal levels by adrenalectomy/castration and inhibition of neurosteroid synthesis enzymes affect sigma1 receptor-mediated behaviour in mice. Eur J Neurosci 1999; 11: 2385-96.
77. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 1996; 16: 1193-202.
78. Urani A, Privat A, Maurice T. The modulation by neurosteroids of the scopolamine-induced learning impairment in mice involves an interaction with sigma1 (σ1) receptors. Brain Res 1998; 799: 64-77.
79. Barker SA, Monti JA, Christian ST. N,N-Dimethyltryptamine: an endogenous hallucinogen. Int Rev Neurobiol 1981; 22: 83-110.
80. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009; 323: 934-7.
81. Su T-P, Hayashi T, Vaupel DB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal 2009; 2: pe12.
82. Smith RL, Canton H, Barrett RJ, Sanders-Bush E. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol Biochem Behav 1998; 61: 323-30.
83. Jenner P, Marsden CD, Thanki CM. Behavioural changes induced by N,N-dimethyl-tryptamine in rodents. Br J Pharmacol 1980; 69: 69-80.
84. Bowen WD, Hellewell SB, McGarry KA. Evidence for a multi-site model of the rat brain sigma receptor. Eur J Pharmacol 1989; 163: 309-18.
85. Largent BL, Gundlach AL, Snyder SH. Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc Natl Acad Sci USA 1984; 81: 4983-7.
86. DeHaven-Hudkins DL, Fleissner LC, Ford-Rice FY. Characterization of the binding of [3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 1992; 227: 371-8.
87. Bowen WD, de Costa BR, Hellewell SB, Walker JM, Rice KC. [3H]-(+)-Pentazocine: A potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol Neuropharmacol 1993; 3: 117-26.
88. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, De Costa BR. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 1995; 280: 301-10.
89. Quirion R, Hammer RP, Jr., Herkenham M, Pert CB. Phencyclidine (angel dust)/sigma opiate receptor: visualization by tritiumsensitive film. Proc Natl Acad Sci USA 1981; 78: 5881-5.
90. Zukin SR, Brady KT, Slifer BL, Balster RL. Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 1984; 294: 174-7.
91. Mendelsohn LG, Kalra V, Johnson BG, Kerchner GA. Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor. J Pharmacol Exp Ther 1985; 233: 597-602.
92. Holtzman SG. Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther 1980; 214: 614-9.
93. Shannon HE. Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 1981; 216: 543-51.
94. Shannon HE. Phencyclidine-like discriminative stimuli of (+)-and (-)-N-allylnormetazocine in rats. Eur J Pharmacol 1982; 84: 225-8.
95. Brady KT, Balster RL, May EL. Stereoisomers of Nallylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 1982; 215: 178-80.
96. Downes CP, Lewis PE, Stone MA. A comparison of the binding of sigma opioids and phencyclidine, and the interaction with antipsychotic drugs in rat brain membranes. Br J Pharmacol 1986; 88: 231-7.
97. Gundlach AL, Largent BL, Snyder SH. Phencyclidine and sigma opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol 1985; 113: 465-6.
98. Sircar R, Nichtenhauser R, Ieni JR, Zukin SR. Characterization and autoradiographic visualization of (+)-[3H]SKF10,047 binding in rat and mouse brain: further evidence for phencyclidine/sigma opiate receptor commonality. J Pharmacol Exp Ther 1986; 237: 681-8.
99. Aanonsen LM, Seybold VS. Phencyclidine and sigma receptors in rat spinal cord: binding characterization and quantitative autoradiography. Synapse, 1989; 4: 1-10.
100. Manallack DT, Beart PM, Gundlach AL. Psychotomimetic σ-opiates and PCP. Trends Pharmacol Sci 1986; 7: 448-51.
101. Quirion R, Chicheportiche R, Contreras PC, et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci 1987; 10: 444-6.
102. Itzhak Y, Stein I. Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci 1990; 47: 1073-81.
103. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990; 11: 81-6.
104. Wong EH, Knight AR, Woodruff GN. [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 1988; 50: 274-81.
105. Colabufo NA, Contino M, Inglese C, et al. In vitro and ex vivo characterization of sigma-1 and sigma-2 receptors: agonists and antagonists in biological assays. Cent Nerv Syst Agents Med Chem 2009; 9: 161-71.
106. Monnet FP, Debonnel G, Bergeron R, Gronier B, de Montigny C. The effects of sigma ligands and of neuropeptide Y on N-methyl-Daspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussin toxin. Br J Pharmacol 1994; 112: 709-15.
107. Debonnel G, Bergeron R, Monnet FP, De Montigny C. Differential effects of sigma ligands on the N-methyl-D-aspartate response in the CA1 and CA3 regions of the dorsal hippocampus: effect of mossy fiber lesioning. Neuroscience 1996; 71: 977-87.
108. Monnet FP, Blier P, Debonnel G, de Montigny C. Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn-Schmiedeberg's Arch Pharmacol, 1992; 346: 32-9.
109. Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000; 292: 900-11.
110. Tam SW, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 1984; 81: 5618-21.
111. Su TP. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982; 223: 284-90.
112. Bowen WD, Moses EL, Tolentino PJ, Walker JM. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol 1990; 177: 111-8.
113. Largent BL, Wikstrom H, Snowman AM, Snyder SH. Novel antipsychotic drugs share high affinity for sigma receptors. Eur J Pharmacol 1988; 155: 345-7.
114. Su TP. HR 375: a potential antipsychotic drug that interacts with dopamine D2 receptors and sigma-receptors in the brain. Neurosci Lett 1986; 71: 224-8.
115. Taylor DP, Dekleva J. Potential antipsychotic BMY 14802 selectively binds to sigma sites. Drug Dev Res 1987; 11: 65-70.
116. Chavkin C. The sigma enigma: biochemical and functional correlates emerge for the haloperidol-sensitive sigma binding site. Trends Pharmacol Sci 1990; 11: 213-5.
117. Ferris RM, Harfenist M, McKenzie GM, Cooper B, Soroko FE, Maxwell RA. BW234U,(cis-9-[3-(3,5-dimethyl-1-piperazinyl) propyl]carbazole dihydrochloride): a novel antipsychotic agent. J Pharm Pharmacol 1982; 34: 388-90.
118. Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Rev, 2004; 10: 1-22.
119. Guy W, Manov G, Wilson WH, et al. Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose-range study. Drug Dev Res 1983; 3: 245-52.
120. Chouinard G, Annable L. An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology (Berl) 1984; 84: 282-4.
121. Schwarcz G, Halaris A, Dren A, Manberg P. Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics. Drug Dev Res 1985; 5: 387-93.
122. Munetz MR, Schulz SC, Bellin M, Harty I. Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Dev Res 1989; 16: 79-83.
123. Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull 1991; 27: 103-6.
124. Ferris RM, Tang FL, Chang KJ, Russell A. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci 1986; 38: 2329-37.
125. Husbands SM, Izenwasser S, Kopajtic T, et al. Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl] carbazole (rimcazole) analogues. J Med Chem 1999; 42: 4446-55.
126. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC. The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther 2000; 292: 803-9.
127. Bartoszyk GD, Bender HM, Hellmann J, Schnorr C, Seyfried CA. EMD 57445: A selective sigma receptor ligand with the profile of an atypical neuroleptic. CNS Drug Rev 1996; 2: 175-94.
128. Maj J, Rogoz Z, Skuza G, Mazela H. Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. Eur J Pharmacol 1996; 315: 235-43.
129. Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology (Berl) 1997; 132: 82-8.
130. Huber MT, Gotthardt U, Schreiber W, Krieg JC. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry 1999; 32: 68-72.
131. Muller MJ, Grunder G, Wetzel H, et al. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res 1999; 89: 275-80.
132. Grunder G, Muller MJ, Andreas J, et al. Occupancy of striatal D2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psycho-pharmacology (Berl) 1999; 146: 81-6.
133. Gewirtz GR, Gorman JM, Volavka J, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 1994; 10: 37-40.
134. Guitart X, Codony X, Ballarin M, Dordal A, Farre AJ. E-5842: a new potent and preferential sigma ligand. Preclinical pharmacological profile. CNS Drug Rev 1998; 4: 201-24.
135. Guitart X, Ballarin M, Codony X, et al. E-5842: antipsychotic σ-receptor ligand. Drugs Fut 1999; 24: 386-92.
136. Beckett S. E-5842. IDrugs 2000; 3: 666-8.
137. Takahashi S, Sonehara K, Takagi K, et al. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors. Psychopharmacology (Berl) 1999; 145: 295-302.
138. Karasawa J, Takahashi S, Horikomi K. Binding properties of [3H]MS-377, a novel sigma receptor ligand, to rat brain membranes. Eur J Pharmacol 2000; 400: 51-7.
139. Takahashi S, Takagi K, Horikomi K. Effects of a novel, selective, sigma1-ligand, MS-377, on phencyclidine-induced behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 2001; 364: 81-6.
140. Karasawa J, Takahashi S, Takagi K, Horikomi K. Effects of [1][1] receptor ligand MS-377 on D2 antagonists-induced behaviors. Pharmacol Biochem Behav 2002; 73: 505-10.
141. Matsumoto RR, Hemstreet MK, Lai NL, et al. Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 1990; 36: 151-5.
142. Tran TT, de Costa BR, Matsumoto RR. Microinjection of sigma ligands into cranial nerve nuclei produces vacuous chewing in rats. Psychopharmacology (Berl) 1998; 137: 191-200.
143. Ishiguro H, Ohtsuki T, Toru M, et al. Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett 1998; 257: 45-8.
144. Ohmori O, Shinkai T, Suzuki T, et al. Polymorphisms of the [1][1] receptor gene in schizophrenia: An association study. Am J Med Genet 2000; 96: 118-22.
145. Uchida N, Ujike H, Nakata K, et al. No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry 2003; 3: 13.
146. Satoh F, Miyatake R, Furukawa A, Suwaki H. Lack of association between sigma receptor gene variants and schizophrenia. Psychiatry Clin Neurosci 2004; 58: 359-63.
147. Frieboes R-M, Steiger A. The antipsychotic effects of sigma drugs. In: Lidow MS, Ed. Neurotransmitter receptors in actions of antipsychotic medications. Boca Raton: CRC Press 2000; pp. 137-152.
148. Leonard BE. The potential contribution of sigma receptors to antidepressant actions. Antidepressants 1997: 159-72.
149. Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 2004; 37 (Suppl 3): S208-13.
150. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005; 10: 319-23.
151. Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Invest Drugs 2009; 18: 767-88.
152. Fishback JA, Robson MJ, Xu Y-T, Matsumoto RR. Sigma receptors: Potential targets for a new class of antidepressant drug. Pharmacol Ther 2010; 127: 271-82.
153. Schmidt A, Lebel L, Koe BK, Seeger T, Heym J. Sertraline potently displaces (+)-[3H]3-PPP binding to sigma sites in rat brain. Eur J Pharmacol 1989; 165: 335-6.
154. Itzhak Y, Kassim CO. Clorgyline displays high affinity for sigma binding sites in C57BL/6 mouse brain. Eur J Pharmacol 1990; 176: 107-8.
155. Sanchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl) 1997; 129: 197-205.
156. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307: 117-9.
157. Shirayama Y, Nishikawa T, Umino A, Takahashi K. pchlorophenylalanine-reversible reduction of sigma binding sites by chronic imipramine treatment in rat brain. Eur J Pharmacol 1993; 237: 117-26.
158. Langa F, Codony X, Tovar V, et al. Generation and phenotypic analysis of sigma receptor type I (σ1) knockout mice. Eur J Neurosci 2003; 18: 2188-96.
159. Sabino V, Cottone P, Parylak SL, Steardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 2009; 198: 472-6.
160. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 2005; 177: 245-55.
161. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625.
162. Kulkarni SK, Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1248-54.
163. Matsuno K, Kobayashi T, Tanaka MK, Mita S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996; 312: 267-71.
164. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by σ1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298: 1269-79.
165. Wang J, Mack AL, Coop A, Matsumoto RR. Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice. Eur Neuropsychopharmacol 2007; 17: 708-16.
166. Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998; 61: 247-52.
167. Oshiro Y, Sakurai Y, Sato S, et al. 3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone and its derivatives. J Med Chem 2000; 43: 177-89.
168. Tottori K, Miwa T, Uwahodo Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001; 41: 976-88.
169. Bermack JE, Haddjeri N, Debonnel G. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl] propyl]-5-methoxy-3,4-dihydro-2-quinolino ne monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus. J Pharmacol Exp Ther 2004; 310: 578-83.
170. Skuza G, Rogoz Z. Antidepressant-like effect of combined treatment with selective sigma receptor agonists and a 5-HT1A receptor agonist in the forced swimming test in rats. Pharmacol Rep 2007; 59: 773-7.
171. Sanchez C, Papp M. The selective σ2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol 2000; 11: 117-24.
172. Sanchez C, Arnt J, Costall B, et al. The selective σ2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther 1997; 283: 1323-32.
173. Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM. Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol Biochem Behav 1989; 32: 777-85.
174. Codony X, Fisas A, Ruiz MT, Guitart X, Farre AJ. Anxiolytic-like effects of E-5842, a selective σ1 ligand with antipsychotic profile. Behav Pharmacol, 2000; 11: 334-5.
175. Perfumi M, Panocka I, Ciccocioppo R, Vitali D, Froldi R, Massi M. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of Hypericum perforatum on alcohol intake in rats. Alcohol Alcohol 2001; 36: 199-206.
176. Raffa RB. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals σ receptor binding. Life Sciences 1998; 62: PL265-70.
177. Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T. In vitro binding studies with two hypericum perforatum extracts-hyperforin, hypericin and biapigenin-on 5-HT6, 5-HT7, GABAA/ benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001; 34 (Suppl 1): S45-8.
178. Mennini T, Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci 2004; 75: 1021-7.
179. Holoubek G, Muller WE. Specific modulation of sigma binding sites by the anxiolytic drug opipramol. J Neural Transm 2003; 110: 1169-79.
180. Mueller WE, Siebert B, Holoubek G, Gentsch C. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry 2004; 37: S189-97.
181. Matsumoto RR. Targeting sigma receptors: novel medication development for drug abuse and addiction. Expert Rev Clin Pharmacol 2009; 2: 351-8.
182. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. Involvement of sigma (σ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 2005; 49: 638-45.
183. Brammer MK, Gilmore DL, Matsumoto RR. Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors. Eur J Pharmacol, 2006; 553: 141-5.
184. Witkin JM. Pharmacotherapy of cocaine abuse: preclinical development. Neurosci Biobehav Rev 1994; 18: 121-42.
185. Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR. Sigma(1) (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26: 499-527.
186. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. Sigma receptors: potential medications development target for anticocaine agents. Eur J Pharmacol, 2003; 469: 1-12.
187. Romieu P, Maurice T. The sigma1 (σ1) protein as a new target for anti-cocaine therapy. In: Pizzoli LA, Ed. Cocaine and heroin abuse research. Hauppauge, NY: Nova Science Publishers 2006; pp. 37-60.
188. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003; 479: 23-40.
189. Sharkey J, Glen KA, Wolfe S, Kuhar MJ. Cocaine binding at sigma receptors. Eur J Pharmacol 1988; 149: 171-4.
190. Chen Y, Hajipour AR, Sievert MK, Arbabian M, Ruoho AE. Characterization of the cocaine binding site on the sigma-1 receptor. Biochemistry 2007; 46: 3532-42.
191. Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002; 42: 1043-55.
192. Mittleman RE, Wetli CV. Death caused by recreational cocaine use: an update. J Am Med Assoc 1984; 252: 1889-93.
193. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56: 613-72.
194. Romieu P, Martin-Fardon R, Maurice T. Involvement of the σ1 receptor in the cocaine-induced conditioned place preference. Neuroreport 2000; 11: 2885-8.
195. Romieu P, Phan VL, Martin-Fardon R, Maurice T. Involvement of the σ1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002; 26: 444-55.
196. Romieu P, Martin-Fardon R, Bowen WD, Maurice T. σ1 receptorrelated neuroactive steroids modulate cocaine-induced reward. J Neurosci 2003; 23: 3572-6.
197. Romieu P, Meunier J, Garcia D, et al. The sigma1 (σ1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacology (Berl) 2004; 175: 154-62.
198. McCracken KA, Bowen WD, Matsumoto RR. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur J Pharmacol 1999; 365: 35-8.
199. McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol 1999; 370: 225-32.
200. Matsumoto RR, Mack AL. (+/-)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur J Pharmacol 2001; 417: R1-2.
201. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting σ1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 2001; 419: 163-74.
202. Matsumoto RR, McCracken KA, Pouw B, et al. N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol 2001; 411: 261-73.
203. Matsumoto RR, Gilmore DL, Pouw B, et al. Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice. Eur J Pharmacol 2004; 492: 21-6.
204. Matsumoto RR, Potelleret FH, Mack A, Pouw B, Zhang Y, Bowen WD. Structure-activity comparison of YZ-069, a novel sigma ligand, and four analogs in receptor binding and behavioral studies. Pharmacol Biochem Behav 2004; 77: 775-81.
205. Matsumoto RR, Hewett KL, Pouw B, et al. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 2001; 41: 878-86.
206. Ujike H, Tsuchida K, Akiyama K, Otsuki S. Supersensitivity of sigma receptors after repeated administration of cocaine. Life Sci 1992; 51: PL31-6.
207. Ujike H, Kuroda S, Otsuki S. sigma Receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 1996; 296: 123-8.
208. Maurice T, Romieu P. Involvement of the σ1 receptor in the appetitive effects of cocaine. Pharmacopsychiatry 2004; 37 (Suppl 3): S198-207.
209. Ujike H, Okumura K, Zushi Y, Akiyama K, Otsuki S. Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment. Eur J Pharmacol 1992; 211: 323-8.
210. Ujike H, Kanzaki A, Okumura K, Akiyama K, Otsuki S. Sigma (σ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 1992; 50: PL129-34.
211. Takahashi S, Miwa T, Horikomi K. Involvement of σ1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci Lett 2000; 289: 21-4.
212. Itzhak Y. Repeated methamphetamine-treatment alters brain sigma receptors. Eur J Pharmacol 1993; 230: 243-4.
213. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A. Attenuation of methamphetamine-induced effects through the antagonism of sigma (σ) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 2008; 18: 871-81.
214. Horan B, Gardner EL, Dewey SL, Brodie JD, Ashby CR. The selective σ1 receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (-)-nicotine in rats. Eur J Pharmacol 2001; 426: R1-2.
215. Maurice T, Casalino M, Lacroix M, Romieu P. Involvement of the σ1 receptor in the motivational effects of ethanol in mice. Pharmacol Biochem Behav 2003; 74: 869-76.
216. Sabino V, Cottone P, Zhao Y, Steardo L, Koob GF, Zorrilla EP. Selective reduction of alcohol drinking in Sardinian alcoholpreferring rats by a sigma-1 receptor antagonist. Psychopharmacology (Berl) 2009; 205: 327-335.
217. Sabino V, Cottone P, Zhao Y, et al. The [1]-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 2009; 34: 1482-93.
218. Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 69-102.
219. Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 2005; 16: 1223-6.
220. Wang HH, Chien JW, Chou YC, Liao JF, Chen CF. Anti-amnesic effect of dimemorfan in mice. Br J Pharmacol 2003; 138: 941-9.
221. Phan VL, Urani A, Sandillon F, Privat A, Maurice T. Preserved sigma1 (σ1) receptor expression and behavioral efficacy in the aged C57BL/6 mouse. Neurobiol Aging 2003; 24: 865-81.
222. Maurice T, Phan VL, Noda Y, Yamada K, Privat A, Nabeshima T. The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (σ) receptor ligands involves both σ1 and σ2 sites. Br J Pharmacol 1999; 127: 335-42.
223. Meunier J, Gue M, Recasens M, Maurice T. Attenuation by a sigma1 (σ1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats. Br J Pharmacol, 2004; 142: 689-700.
224. Meunier J, Maurice T. Beneficial effects of the σ1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine. Neurotoxicol Teratol 2004; 26: 783-97.
225. Maurice T. Improving Alzheimer's disease-related cognitive deficits with σ1 receptor agonists. Drug News Perspect 2002; 15: 617-625.
226. Uchida N, Ujike H, Tanaka Y, et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psychiatry 2005; 13: 1062-6.
227. Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 1999; 260: 5-8.
228. Ishikawa M, Sakata M, Ishii K, et al. High occupancy of σ1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009; 12: 1127-31.
229. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2008; 32: 1656-9.
230. Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT. Interaction with σ1 protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 2006; 317: 606-14.
231. Meunier J, Ieni J, Maurice T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther 2006; 317: 1307-19.
232. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid σ 25-35 peptide-induced toxicity in mice involve an interaction with the σ1 receptor. Br J Pharmacol 2006; 149: 998-1012.
233. Matsuno K, Senda T, Kobayashi T, Mita S. Involvement of σ1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res 1995; 690: 200-6.
234. Senda T, Matsuno K, Okamoto K, Kobayashi T, Nakata K, Mita S. Ameliorating effect of SA4503, a novel σ1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur J Pharmacol 1996; 315: 1-10.
235. Matsuno K, Senda T, Kobayashi T, Okamoto K, Nakata K, Mita S. SA4503, a novel cognitive enhancer, with σ1 receptor agonistic properties. Behav Brain Res 1997; 83: 221-4.
236. Maurice T, Su TP, Privat A. Sigma1 ([1]1) receptor agonists and neurosteroids attenuate σ 25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998; 83: 413-28.
237. Maurice T, Phan VL, Privat A. The anti-amnesic effects of sigma1 (σ1) receptor agonists confirmed by in vivo antisense strategy in the mouse. Brain Res 2001; 898: 113-21.
238. Przuntek H. Non-dopaminergic therapy in Parkinson's disease. J Neurol, 2000; 247 (Suppl 2): II19-24.
239. Kornhuber J, Herr B, Thome J, Riederer P. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm Suppl 1995; 46: 131-7.
240. Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the σ1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004; 19: 2212-20.
241. Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 1993; 163: 129-31.
242. DeHaven-Hudkins DL, Hudkins RL. Binding of dexetimide and levetimide to [3H](+)pentazocine-and [3H]1,3-di(2-tolyl)guanidinedefined sigma recognition sites. Life Sci 1991; 49: PL135-9.
243. Chien CC, Pasternak GW. Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid σ1 system. Eur J Pharmacol 1993; 250: R7-8.
244. Chien CC, Pasternak GW. Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther 1994; 271: 1583-90.
245. Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 1995; 190: 137-9.
246. Mei J, Pasternak GW. σ1 Receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 2002; 300: 1070-4.
247. King M, Pan YX, Mei J, Chang A, Xu J, Pasternak GW. Enhanced kappa-opioid receptor-mediated analgesia by antisense targeting the σ1 receptor. Eur J Pharmacol 1997; 331: R5-6.
248. Díaz JL, Zamanillo D, Corbera J, et al. Selective sigma1 (σ1) receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009; 9: 172-183.
249. Roh DH, Kim HW, Yoon SY, et al. Intrathecal injection of the σ1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology 2008; 109: 879-89.
250. Drews E, Zimmer A. Central sensitization needs sigma receptors. Pain 2009; 145: 269-70.
251. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-81.
252. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. The Lancet 1999; 353: 1959-64.
253. Entrena JM, Cobos EJ, Nieto FR, et al. σ1 receptors are essential for capsaicin-induced mechanical hypersensitivity: Studies with selective σ1 ligands and sigma-1 knockout mice. Pain 2009; 143: 252-61.
254. Cendan CM, Pujalte JM, Portillo-Salido E, Montoliu L, Baeyens JM. Formalin-induced pain is reduced in [1] receptor knockout mice. Eur J Pharmacol 2005; 511: 73-4.
255. de la Puente B, Nadal X, Portillo-Salido E, et al. σ1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 2009; 145: 294-303.
256. Johannessen M, Fontanilla D, Mavlyutov T, Ruoho AE, Jackson MB. Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels. Am J Physiol Cell Physiol 2011; 300: C328-37.
257. Noda Y, Kamei H, Kamei Y, Nagai T, Nishida M, Nabeshima T. Neurosteroids ameliorate conditioned fear stress: an association with sigma receptors. Neuropsychopharmacology 2000; 23: 276-84.
258. Akunne HC, Whetzel SZ, Wiley JN, et al. The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 1997; 36: 51-62.
259. Chien CC, Pasternak GW. (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol 1995; 294: 303-8.
260. Colabufo NA, Berardi F, Contino M, et al. Antiproliferative and cytotoxic effects of some σ2 agonists and σ1 antagonists in tumour cell lines. Naunyn-Schmiedeberg's Arch Pharmacol 2004; 370: 106-13.
261. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) 2004; 174: 301-19.
262. Yevich JP, New JS, Lobeck WG, et al. Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents. J Med Chem 1992; 35: 4516-25.
263. Chaki S, Tanaka M, Muramatsu M, Otomo S. NE-100, a novel potent sigma ligand, preferentially binds to sigma 1 binding sites in guinea pig brain. Eur J Pharmacol 1994; 251: R1-2.
264. Okuyama S, Nakazato A. NE-100: A novel sigma receptor antagonist. CNS Drug Rev 1996; 2: 226-37.
265. Berardi F, Ferorelli S, Colabufo NA, Leopoldo M, Perrone R, Tortorella V. A multireceptorial binding reinvestigation on an extended class of sigma ligands: N-[σ-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards sigma1 and EBP sites. Bioorg Med Chem 2001; 9: 1325-35.
266. Perregaard J, Moltzen EK, Meier E, Sanchez C. Sigma ligands with subnanomolar affinity and preference for the σ2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem 1995; 38: 1998-2008.
267. Mach RH, Wu L, West T, Whirrett BR, Childers SR. The analgesic tropane analogue (+/-)-SM 21 has a high affinity for σ2 receptors. Life Sci 1999; 64: PL131-7.
268. Matsumoto RR, Pouw B, Mack AL, Daniels A, Coop A. Effects of UMB24 and (+/-)-SM 21, putative σ2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice. Pharmacol Biochem Behav 2007; 86: 86-91.
269. Zhang Y, Williams W, Torrence-Campbell C, Bowen WD, Rice KC. Characterization of novel N,N'-disubstituted piperazines as sigma receptor ligands. J Med Chem 1998; 41: 4950-7.
270. Su TP, Wu XZ, Cone EJ, et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J Pharmacol Exp Ther 1991; 259: 543-50.